Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $165. The reaffirmation of the Neutral stance and price target suggests that the analyst sees the stock trading around current levels in the near term.
December 14, 2023 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Olivia Brayer has maintained a Neutral rating and a $165 price target for Alnylam Pharmaceuticals (NASDAQ:ALNY).
The reiteration of a Neutral rating typically indicates that the analyst believes the stock will not experience significant price movement in either direction in the short term. The maintained price target of $165 suggests that the analyst does not foresee substantial changes in the company's valuation or stock price from current levels. Investors may view this as a sign of stability or lack of immediate growth prospects.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100